- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHIMERIC THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | CHIMERIC THERAPEUTICS LIMITED: Notification regarding unquoted securities - CHM | - | ASX | ||
| Fr | CHIMERIC THERAPEUTICS LIMITED: Notification regarding unquoted securities - CHM | - | ASX | ||
| Do | Chimeric Therapeutics (ASX:CHM) posts 40% tumour shrinkage at top dose in CAR-T trial | 2 | Stocks Down Under | ||
| Do | CHIMERIC THERAPEUTICS LIMITED: CHM CDH17 Phase 1 clinical trial update - New DL 3 data | - | ASX | ||
| Di | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| Di | CHIMERIC THERAPEUTICS LIMITED: Notification of cessation of securities - CHM | - | ASX | ||
| 07.07. | CHIMERIC THERAPEUTICS LIMITED: Final Director's Interest Notice | - | ASX | ||
| 06.07. | CHIMERIC THERAPEUTICS LIMITED: Board Update | - | ASX | ||
| 02.07. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 01.07. | CHIMERIC THERAPEUTICS LIMITED: Appointment of Financial Adviser for Strategic Review | - | ASX | ||
| 11.06. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 01.06. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 31.05. | CHIMERIC THERAPEUTICS LIMITED: CHM announces positive Phase 1/2 data at ASCO | - | ASX | ||
| 20.05. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 12.05. | CHIMERIC THERAPEUTICS LIMITED: Notice under section 708A | - | ASX | ||
| 12.05. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 12.05. | CHIMERIC THERAPEUTICS LIMITED: Application for quotation of securities - CHM | - | ASX | ||
| 08.05. | CHIMERIC THERAPEUTICS LIMITED: Proposed issue of securities - CHM | - | ASX | ||
| 05.05. | CHIMERIC THERAPEUTICS LIMITED: Notification of cessation of securities - CHM | - | ASX | ||
| 05.05. | CHIMERIC THERAPEUTICS LIMITED: Change in substantial holding | - | ASX |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,965 | -0,55 % | Siemens Energy fällt zurück, Qiagen zieht an: DAX-Ausblick | Der DAX ist nach seinem Rekordlauf in der vergangenen Woche wieder etwas zurückgekommen. Unter dem Strich büßte das größte deutsche Börsenbarometer unter dem Strich mehr als 700 Punkte ein und schloss... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,99 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 19,160 | -0,05 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| TREVI THERAPEUTICS | 19,075 | +0,03 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,500 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,060 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,42 | +0,00 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| KYMERA THERAPEUTICS | 115,77 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,530 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,490 | -0,25 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an | ||
| NURIX THERAPEUTICS | 23,120 | 0,00 % | Mizuho hebt Kursziel für Nurix nach Roche-Deal auf 34 US-Dollar an | ||
| ARRIVENT BIOPHARMA | 33,190 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,960 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| CG ONCOLOGY | 71,92 | +0,10 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 42,620 | 0,00 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen |
Das Unternehmen CHIMERIC THERAPEUTICS LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHIMERIC THERAPEUTICS LIMITED finden Sie auf Wallstreet Online.